SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (βNGM Bioβ) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.54 | 1.54 | 1.54 | 0 | 0 | CS |
4 | 0 | 0 | 1.54 | 1.54 | 1.54 | 0 | 0 | CS |
12 | 0 | 0 | 1.54 | 1.54 | 1.54 | 0 | 0 | CS |
26 | -0.02 | -1.28205128205 | 1.56 | 1.63 | 1.53 | 89179 | 1.57319132 | CS |
52 | 0.5 | 48.0769230769 | 1.04 | 2.2 | 0.6002 | 506005 | 1.3121408 | CS |
156 | -20.83 | -93.1157800626 | 22.37 | 22.905 | 0.6002 | 449943 | 6.3670209 | CS |
260 | -15.07 | -90.7284768212 | 16.61 | 32.12 | 0.6002 | 386923 | 10.60285774 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.